Sam Brusco, Associate Editor04.30.24
LivaNova has revealed that Ahmet Tezel, Ph.D. will join the company as chief innovation officer, beginning May 13, 2024.
The newly created position will leverage Tezel’s career of over 20 years in R&D to establish an integrated innovation function at LivaNova to bolster the company’s development of new technologies. Tezel will join the LivaNova executive leadership team.
Tezel was most recently Company Group Chairman at Johnson & Johnson MedTech, leading its global R&D and innovation teams. He has served in executive R&D roles at several healthcare companies, including Ethicon, Alcon, and Allergan, developing Class III implantables and complex capital equipment.
“I am very pleased to welcome Ahmet to the LivaNova team,” said LivaNova CEO Vladimir Makatsaria. “At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advancing this vision. With a remarkable track record, Ahmet has led teams that have developed market-leading technologies across diverse medical domains, from bariatric surgery to surgical ophthalmology. As Chief Innovation Officer, Ahmet will advance LivaNova’s ability to create novel solutions and elevate the quality of care in neurological and cardiac health for patients around the world.”
“I look forward to this new chapter at LivaNova, working with the team to harness their motivations and talents to drive innovative product development that creates long-term value for the company and aligns with its mission,” said Tezel. “I am honored to join a company that has a profound impact on patients.”
Last week, LivaNova provided notice to U.S. patients concerning a cybersecurity incident initially revealed on November 20, 2023.
The newly created position will leverage Tezel’s career of over 20 years in R&D to establish an integrated innovation function at LivaNova to bolster the company’s development of new technologies. Tezel will join the LivaNova executive leadership team.
Tezel was most recently Company Group Chairman at Johnson & Johnson MedTech, leading its global R&D and innovation teams. He has served in executive R&D roles at several healthcare companies, including Ethicon, Alcon, and Allergan, developing Class III implantables and complex capital equipment.
“I am very pleased to welcome Ahmet to the LivaNova team,” said LivaNova CEO Vladimir Makatsaria. “At LivaNova, our commitment to pioneering innovation remains unwavering, and Ahmet's arrival marks a significant step in advancing this vision. With a remarkable track record, Ahmet has led teams that have developed market-leading technologies across diverse medical domains, from bariatric surgery to surgical ophthalmology. As Chief Innovation Officer, Ahmet will advance LivaNova’s ability to create novel solutions and elevate the quality of care in neurological and cardiac health for patients around the world.”
“I look forward to this new chapter at LivaNova, working with the team to harness their motivations and talents to drive innovative product development that creates long-term value for the company and aligns with its mission,” said Tezel. “I am honored to join a company that has a profound impact on patients.”
Last week, LivaNova provided notice to U.S. patients concerning a cybersecurity incident initially revealed on November 20, 2023.